Jump to content
Powered by
  • Industry report The healthcare industry – the innovation driver of the 21st century: opportunities and challenges

    BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English.

  • Publications Selected publications

    Here you can find selected publications on the Baden-Württemberg healthcare industry.

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.

  • Dossier Immunology – at the forefront of medical progress

    Immunological approaches are central to everything – learn more!

Register now!

Strasbourg, France
Anmeldefrist:

Focusing on novel therapeutic and diagnostic immunological approaches to fight cancer, our 18. joint event with BioValley France will take place on the 3rd of December, 2020 in Strasbourg. Apply for a short presentation!

Latest news

  • Affimed GmbH - 01/07/2020

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

  • SICOS BW GmbH - 18/06/2020

    In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

  • Press release - 17/06/2020

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

  • Press release - 15/06/2020

    The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

  • Innovations in the field of endoscopy - 08/06/2020

    A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

Website address: https://www.gesundheitsindustrie-bw.de/en